Mast cells (MCs) have been identified in various tumors; however, the role of these cells in tumorigenesis remains controversial. Here, we quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and function of these cells in MPE development. Evaluation of murine MPE-competent lung and colon adenocarcinomas revealed that these tumors actively attract and subsequently degranulate MCs in the pleural space by elaborating CCL2 and osteopontin. MCs were required for effusion development, as MPEs did not form in mice lacking MCs, and pleural infusion of MCs with MPEincompetent cells promoted MPE formation. Once homed to the pleural space, MCs released tryptase AB1 and IL-1b, which in turn induced pleural vasculature leakiness and triggered NF-kB activation in pleural tumor cells, thereby fostering pleural fluid accumulation and tumor growth. Evaluation of human effusions revealed that MCs are elevated in MPEs compared with benign effusions. Moreover, MC abundance correlated with MPE formation in a human cancer cell-induced effusion model. Treatment of mice with the c-KIT inhibitor imatinib mesylate limited effusion precipitation by mouse and human adenocarcinoma cells. Together, the results of this study indicate that MCs are required for MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable.
Introduction
Inflammation was recently recognized as an enabling hallmark of cancer that may mediate tumor growth and dissemination instead of tumor eradication (1) . Inflammatory signaling networks in the tumor microenvironment can be initiated and orchestrated by malignant or immune cells; the networks conditionally facilitate tumor progression or regression depending on tumor type, immune effector cell type, and anatomic context (2) (3) (4) . The identification of such inflammatory loops is of particular interest in the hunt for anticancer therapies that are anticipated to be more effective and less toxic than conventional chemotherapy (5) .
In addition to macrophages, neutrophils, and lymphocytes, mast cells (MCs) were recently found to be recruited to pancreatic and other tumors and to facilitate tumor growth (6, 7) . Although they are relatively sparse, MCs are appealing candidates for tumor promotion, since they can release a battery of mediators to orchestrate the tumor milieu (8) (9) (10) (11) . However, MCs were found to be tumor-protective or indifferent in other settings (12) (13) (14) . While the reasons for the divergent MC functions in cancer are not known, new models of MC deficiency lend promise to solve this riddle (15, 16) .
Malignant pleural effusion (MPE) is extremely common in patients with lung, breast, or other adenocarcinomas (17, 18) . No treatment exists, and palliative attempts may cause further morbidity and mortality (19, 20) . MPE was recently reclassified as a separate stage of lung cancer, since it was acknowledged to represent a distinct form of metastatic disease with very short survival (18, 21, 22) . Simultaneously, we and others used mouse models to hypothesize that MPE is primarily an immune-and vascularMast cells (MCs) have been identified in various tumors; however, the role of these cells in tumorigenesis remains controversial. Here, we quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and function of these cells in MPE development. Evaluation of murine MPE-competent lung and colon adenocarcinomas revealed that these tumors actively attract and subsequently degranulate MCs in the pleural space by elaborating CCL2 and osteopontin. MCs were required for effusion development, as MPEs did not form in mice lacking MCs, and pleural infusion of MCs with MPE-incompetent cells promoted MPE formation. Once homed to the pleural space, MCs released tryptase AB1 and IL-1β, which in turn induced pleural vasculature leakiness and triggered NF-κB activation in pleural tumor cells, thereby fostering pleural fluid accumulation and tumor growth. Evaluation of human effusions revealed that MCs are elevated in MPEs compared with benign effusions. Moreover, MC abundance correlated with MPE formation in a human cancer cellinduced effusion model. Treatment of mice with the c-KIT inhibitor imatinib mesylate limited effusion precipitation by mouse and human adenocarcinoma cells. Together, the results of this study indicate that MCs are required for MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable.
Mast cells mediate malignant pleural effusion formation
Anastasios D. Giannou, 1 Antonia Marazioti, 1 Magda Spella, 1 Nikolaos I. Kanellakis, 2 Hara Apostolopoulou, 1 Ioannis Psallidas, effusions from congestive heart failure (CHF; Figure 1A ). Increased MC numbers were also identified in 2 different mouse models of MPEs that develop 14 days after intrapleural delivery of syngeneic Lewis lung carcinoma (LLC; 30,310 ± 30,440 MC/cavity) or MC38 colon (36,590 ± 27,690 MC/cavity adenocarcinoma) cells (25, 26) , compared with controls injected with MPE-incompetent B16F10 melanoma cells (999 ± 1,008/cavity) or saline (755 ± 384/cavity; n = 3). In addition, MC abundance was correlated with the volume of experimental effusions (Figure 1B) . MPE MCs displayed typical morphology and TB/c-KIT staining, but they were easily overlooked when MGG, Wright, or other conventional staining was employed ( Figure 1 , C and D, and Figure 2A ). MPE MCs were identified as CD45 + c-KIT + Sca1 + Lin -by flow cytometry (27) (28) (29) , were reduced in c-KIT-defective c-Kit Wsh mice (30) , and were completely absent from MC-eradicated Cpa3
Cre/+ mice (15) -a mouse model of more complete and selective MC deficiency as compared with c-Kit Wsh micethat were challenged with pleural adenocarcinoma cells (Figure 2B ). In mice with MPEs, MCs were preferentially located in mediated manifestation of pleural-metastasized cancers (23, 24) . However, the immune cells that drive MPE remain unidentified.
Here we describe the discovery of MCs in human and mouse MPEs and the elucidation of their fate and role. We show that MCs are driver cells required for MPEs and uncover the key messengers that instate tumor-MC circuitry during MPE development. Importantly, we provide proof-of-concept data supporting that MC-dependent MPEs are targetable using existing drugs; these data lend promise for translational applications of our findings.
Results

MCs in MPEs.
MCs were encountered on May-Gruenwald-Giemsa-stained (MGG-stained) archival specimens of human MPEs from our pleural patient biobank. To rule out a local artifact, MCs were verified on metachromatic toluidine bluestained (TB-stained) MPE samples from a different hospital. Systematic evaluation of samples and data from our pleural patient biobank revealed substantial MC numbers (millions/cavity) in MPEs that were significantly elevated compared with benign occasions (biological n = 2) by microarray analysis. Although 39 genes were overrepresented in MPE-competent adenocarcinoma cells on both occasions, only 2 RNAs possessed cytokine/ chemokine activity required for systemic MC recruitment and were selected for further study: Spp1 and Ccl2 (encoding osteopontin, or secreted phosphoprotein 1 [SPP1], and CCL2, respectively; Figure 6A and Supplemental Tables 1 and 2) . ELISA of tumor cell-conditioned media (CM) validated the microarray, and serum ELISA of pleural tumor-bearing C57BL/6 mice identified a significant difference in serum CCL2, but not SPP1, between adenocarcinoma-and melanoma-bearing mice ( Figure  6 , B and C). In modified mastotaxis assays (36) , tracer BMMCs migrated toward LLC cells expressing random and anti-Spp1 shRNA (sh), but not toward B16F10 cells or LLC cells expressing shCcl2 ( Figure 6D and Figure 7A ), implicating CCL2 in MPEdirected mastotaxis. Indeed, forced expression of Ccl2 plasmid (p) in B16F10 cells restored, and forced expression of shCcl2 in LLC cells inhibited, MPE (25) and MC accumulation. (Figure 7 , B and C). Moreover, treatment of mice harboring pleural LLC cells with i.p. CCL2-and/or CCL12-neutralizing Ab (37) blocked MPE (38) and MC accumulation, and direct pleural-delivered recombinant mouse (rm) CCL2 attracted MCs (Figure 7 , D-F). Finally, CCL2 (but not SPP1) levels were correlated with MC abundance in human MPEs ( Figure 7G ). Collectively, these data indicated that CCL2 is a key tumor-secreted MC attractant to the pleural space.
MCs are required for MPEs. We next investigated MC effects on effusion formation. Pleural co-delivery of BMMCs facilitated induction of MPE by B16F10 cells, which are naturally MPE incompetent, without fully instilling the phenotype of adenocarcinoma cells ( Figure 8A (Figure 5C ). Hence, pleural adenocarcinomas remotely mobilize/ recruit MCs via circulating messengers.
CCL2 as an adenocarcinoma-derived mastokine. To identify these messengers, effusion-competent and effusion-incompetent tumor cells were transcriptionally profiled on 2 different Cre/+ mice were MC-eradicated ( Figure 8 , B and C Figure 8F ), resembling mice were protected against MPEs induced by both LLC and MC38 adenocarcinomas ( Figure 8 , B and C). In addition to MPE accumulation, MC deficiency resulted in retardation of pleural tumor growth, evident macroscopically ( Figure 8 , B and C), but also by decreased proliferating cell nuclear antigen (PCNA) immunoreactivity ( Figure 8D ). here in multiple ways that tumor-secreted SPP1 promoted MC activation and degranulation. Adenocarcinoma cell-CM caused SPP1-dependent BMMC degranulation, and rmSPP1 directly degranulated BMMCs ( Figure 10 and Supplemental Video 3). SPP1 effects were only partial, indicating the presence of additional tumor-elicited players in MC activation. Collectively with our past work, these data established dual functions of tumorderived SPP1 during effusion development: in addition to inducing vascular leakage, osteopontin degranulates MCs.
Adenocarcinoma-primed MCs secrete tryptase AB1 and IL-1β to foster MPEs.
To identify how pleural adenocarcinoma-recruited and pleural adenocarcinoma-primed MCs mediate effusion development, 2 different BMMC cultures were exposed to tumor-CM and were profiled transcriptionally (biological n = 2). Four BMMC transcripts were induced specifically and consistently by adenocarcinoma-CM, including secretory genes Tpsab1 and Il1b and membrane/granule-associated Cd68 (Figure 11A and Supplemental Tables 3-5) . Indeed, adenocarcinoma-CM caused IL-1β release by BMMCs in a SPP1-dependent fashion, and adenocarcinoma-induced MPEs featured substantial IL-1β levels, which were reduced in c-Kit Wsh mice ( Figure 11 Cre/+ mice. In multiple MC reconstitution experiments, C57BL/6 -but not MC-like innate immune cells described previously (29) . We also sought to compare the relative contributions of MCs with those of macrophages during MPE development, since macrophages are the predominant cellular population in MPEs and are also chemoattracted to the pleural space by tumor-derived CCL2 (23, 25) . For this, mice expressing Cre recombinase under the drive of the Lyz2 promoter were crossed with mice expressing Diphtheria toxin selectively in somatic cells that undergo Cre-mediated recombination to generate a macrophage ablation model (Lyz2-Cre and R26-DTA, respectively; refs. 41, 42) . Pleural macrophages of naive C57BL/6 mice were predominantly F4/80 + and CD11b
+ , but not CD11c + ; F4/80 + CD11b + pleural cells were markedly diminished in Lyz2-Cre R26-DTA mice compared with single transgenic controls ( Figure 9A ). Interestingly, Lyz2-Cre R26-DTA mice were protected against MPEs induced by both LLC and MC38 adenocarcinomas to a degree comparable to both mouse models of MC deficiency ( Figure 9B ). Hence, MCs are required for effusion formation, and they are equally important with much more prevalent cell types, such as macrophages.
In addition, c-Kit
Wsh and Cpa3 Cre/+ mice can serve as tumor models of MC depletion and eradication, respectively.
Tumor-secreted osteopontin causes MC degranulation. We next examined the role of tumor-originated osteopontin (encoded by the SPP1 gene in humans and the Spp1 gene in mice) -the other candidate detected by tumor cell microarray -in MC-dependent effusions. We had previously identified that SPP1 is a marked mediator of vascular permeability that leads to MPE accumulation (43) . In addition to its vasoactive effects, we determined Figure 11I ). rmIL-1β did not induce skin vessel leakage in C57BL/6 mice; on the contrary, rm tryptase AB1 (TPSAB1) did not affect cell proliferation (data not shown), but induced marked vascular hyperpermeability comparable to rmVEGF ( Figure 11J ). These results indicated that c-KIT-competent MCs facilitate MPE development by secreting TPSAB1 and IL-1β to foster vascular permeability and tumor growth, respectively.
MC-derived IL-1β activates NF-κΒ in pleural adenocarcinoma cells. NF-κB responds to IL-1α in cancer cells (45) and augments tumor growth and MPEs (46, 47) . To test whether MC-derived products activate NF-κB and other important transcription pathways of tumor cells, such as STAT3 and NOTCH, we assessed the expression of 12 target genes of the above pathways by qPCR before and after 4 hours of treatment with BMMC-CM. Interestingly, none of the 12 genes examined was inducible by BMMC-CM in MPE-defective B16F10 cells; however, both NF-κB-target gene Ccl2 and STAT3-target gene Myc were strongly upregulated by BMMC-CM selectively in MPE-competent adenocarcinoma cells ( Figure 12A ). By imaging a NF-κB reporter (pNF-κΒ-Luc; refs. 47, 48) and by immunoblotting, IL-1β (and IL-1α) and BMMC coculture induced and/or sustained NF-κB in adenocarcinoma, but not in B16F10 cells; this phenomenon was curtailed when Il1b -/-BMMCs were used and affected multiple NF-κB-pathway components ( Figure 12 , B-D, and Figure  13 ; full, uncut gels can be found in Supplemental Figures). In addition, Il1r1 mRNA was selectively expressed by adenocarcinoma, but not B16F10 cells ( Figure 12E and Supplemental Table  1 ). In vivo imaging of C57BL/6 and c-Kit Wsh mice with pleural LLC cells expressing pNF-κΒ-Luc or a constitutive pCAG-Luc reporter verified that MC deficiency diminished tumor-specific NF-κB activation ( Figure 14A ). We next overexpressed Ikbkb (encoding ΙκB kinase [IKK] β), the main NF-κB-inducing kinase (45) , in adenocarcinoma cells ( Figure 14B ). Ikbkb-overexpressing LLC cells were autonomous from IL-1β for NF-κB activation and equally caused MPEs in C57BL/6, c-Kit Wsh , and Cpa3 
MC-mediated MPEs are actionable.
To investigate whether the proposed pathway is targetable, we used c-KIT inhibitor imatinib mesylate (IM), which is clinically available. IM showed beneficial effects toward limiting LLC-induced effusions, and at the same time hampering pleural MC accumulation and vascular leakiness, when given at physiologically relevant once-daily doses of 1 mg/kg ( Figure 15A ). We also tested IM in the only Figure 15B ). In addition, A549-induced MPEs were responsive to IM regression treatment (1 mg/kg daily) initiated on day 15 after establishment of pleural tumors ( Figure 15C ). Moreover, human MPEs from our biobank contained significantly elevated IL-1β levels compared with matched sera, a phenomenon not observed when CHF or IL-1α levels were examined ( Figure 15D ). In summary, our present work shows that MCs are required for MPEs, attracted to and activated in the pleural space by CCL2 and SPP1 of tumor cell origin. Once in the pleura, MCs secrete TPSAB1 and IL-1β to foster a hyperpermeable microenvironment and tumor NF-κB activation, respectively ( Figure 15E ).
Discussion
Here we report a connection between inflammation and cancer: MCs feed the inflammatory pleural environment fostering MPEs. We consistently found MCs in MPEs of patients and mice, and identified a plausible reason for their previous neglect. We also investigated MC trafficking and determined that these BM cells (49, 50) bed (23, 24) . Indeed, MCs secreted multiple inflammatory and vasoactive mediators upon adenocarcinoma encounter: histamine, a known permeability factor (9); TPSAB1 shown here to induce strong vasoactive effects; and IL-1β, a well-known NF-κB stimulus (45) . Interestingly, the intrapleural levels of MC-originated TPSAB1 identified here may be responsible for the clinically well-known failure of normal, benign, and malignant pleural fluid to spontaneously coagulate, since TPSAB1 was recently found to cleave fibrinogen (53) . Hence, tumor site likely determines MC function in cancer, and the pleural space probably constitutes a preferential theater for deployment of protumor MC effects. Regardless of the tumor milieu, only certain tumor cells were able to initiate bidirectional signaling with MCs in our hands. First, only tumor cells competent of CCL2 secretion were able to attract substantial numbers of MCs to the pleural cavities. The finding of CCL2 as a cardinal MPE mastokine corrobdevelopment. Moreover, it was shown that this less prevalent cellular population is as important for effusion formation as predominant immune cells such as macrophages.
Our data support that substantial populations of MCs exist in MPEs of humans and mice, and that they play a functional tumor-promoting role in the pleural space when the latter is taken over by metastatic tumors. This protumor role of pleural MCs appears to be conditional on the pleural space, since MCs were tumor-indifferent or even exerted antitumor functions in other tumor models (6, 12) . The marked effusion-promoting effects of pleural-accrued MCs may be explained by the vast abundance of MCs in serosal cavities, a preferential site for their isolation (15) . However, it is also conceivable that MCs, potent inflammatory regulators and vasoactors (51, 52) , impact effusion formation more heavily than other tumor models, since MPE is mainly caused by inflammation and vasoactive signaling, and since the pleural cavities feature an extensive vascular together, our data suggest that MPE-prone adenocarcinomas may initiate circuitry with MCs due to coordinated expression of MC chemoattractants (i.e., CCL2) and effectors (i.e., SPP1), as well as the cognate receptors of MC-originated ligands such as IL-1β. The reason behind the propensity of the adenocarcinoma cells studied here to initiate crosstalk with MCs remains to be determined but can explain, together with the site-specificity discussed above, the differential impact of MCs on different tumors. In addition, these results can serve as a paradigm of how tumor-associated inflammatory cells can conditionally orates and expands work that identified CCL2 as the culprit for MC accrual to pancreatic tumors (6, 7). However, CCL2-mediated MC recruitment was not enough for full-blown tumor-MC interactions during MPE development; murine adenocarcinoma cells also secreted SPP1 that facilitated MC degranulation. On the contrary, B16F10 cells were unable to activate codelivered BMMCs, thus failing to mount full effusion-inducing properties, since they were found not to express SPP1. Finally, adenocarcinomas were selectively responsive to MC-originated IL-1β and expressed Il1r1, while melanoma cells did not. Taken 
Methods
Further information can be found in Supplemental Methods.
Reagents. CCL2 and CCL12 neutralizing and IgG2a control Abs (37) were a gift from Oncology Discovery Research, Janssen Research & Development LLC. rmCCL2 was from Peprotech; rmIL-1β, rm IL-3, and rmKITL were from Immunotools; rmSPP1 and rmTPSAB1 were from R&D Systems; C48/80 and Evans' blue were from Sigma-Aldrich; ELISA kits were from Peprotech and R&D Systems; IM was from Selleckchem; and Boyden chambers were from Millipore.
Cells. LLC, B16F10, A549, and SKMEL2 (NCI) and MC38 cells (a gift from Barbara Fingleton, Vanderbilt University, Nashville, Tennessee, USA) (38) were cultured and tested as described in the Supplemental Methods. In vivo injections are described elsewhere (25, 26, 38, 47, 48) . BM cells were flushed from femurs and tibias and cultured in full DMEM with rmIL-3 ± rmKITL (100 ng/ml each). Nonadherent cells were passaged for 4-6 weeks (31).
Animals. (38) . IM (1 mg/kg) was given daily i.p. Anti-mouse CCL2 and CCL12 (a murine CCL2 ortholog) and IgG2a control Abs were delivered i.p. at 50 mg/kg every 3 days (37, 38) . Harvest and pleural lavage are described elsewhere (25, 26, 38, 47, 48) . NF-κB integrates inflammatory stimuli from the tumor microenvironment to pivotally influence tumor cell survival and paracrine inflammatory signaling (54) . In turn, immune cells stimulate tumor NF-κB, reinforcing a "vicious cycle" between tumor progression and inflammation (5, 55) . NF-κB affects MPE progression, stimulated by tumor-and host-originated ligands of an ever-expanding cellular origin (26, 47, 48) . Here we show that MC-secreted IL-1β upregulates NF-κB and cellular proliferation of pleural adenocarcinomas. Using in vivo imaging, we show in real time how MCs fuel tumor cell NF-κB and identify that IKKβ relies on MC-derived IL-1β to sustain the transcription factor. These findings are consistent with the recently reported Nlrp3-mediated IL-1β release by skin MCs (56), and they also strengthen the link between inflammation and cancer by positioning MCs as "feeder cells" of oncogenic NF-κB, as well as other important tumor cell transcription factors, such as STAT3 (57) .
Importantly, the requirement for MCs during MPE development was actionable. Encouraging benefits were obtained from imatinib treatment of mice with syngeneic effusions, and concordant findings were recapitulated in human cancer cell-induced MPEs. These data strengthen the proposed connection and show how MC-targeted therapies can impact nongastrointestinal stromal tumors. The finding of significantly increased MCs and IL-1β in human MPEs compared with both matched serum samples and corresponding samples from patients with CHF suggests that our findings may be applicable to humans with established or impending MPEs, a possibility worth exploring.
In conclusion, we identified the conditional initiation and execution of a circuitry of tumor-initiated, MC-perpetuated inflammatory signaling events that occur during MPE formation. We show how tumor cells co-opt MCs to drive effusion development. In addition to the surprising discovery of MCs as culprits of MPEs, we identify CCL2, SPP1, TPSAB1, IL-1β, and IKKβ as key players in tumor cell-MC interactions in the pleural space. MCs per se, as well as each of the above targets, may present candidates for annihilating the requirement for MCs during MPE formation. Constructs. Random (shC), anti-Ccl2 (shCcl2), or anti-Spp1 (shSpp1) shRNAs, as well as Ccl2 and β-gal expression vectors, have been described (25, 41) . pEGFP and pEGFP.Ikbkb (Addgene IDs 58249 and 58251) were cloned from MC38 total RNA using specific primers (Supplemental Table 7 ). Cells were transfected with 5 μg DNA by X-fect reagent (BD Biosciences -Clontech) and selected by puromycin.
BM cell transfer. logic specimens from 20 patients with lung adenocarcinoma aspirated in 2013. Diagnosis and sample handling are described elsewhere (25, 26, 48) . All protocols abided by the Helsinki Declaration were approved a priori by the relevant IRB and by all patients via written informed consent. Cytology and histology. Cell and tissue specimens, prepared as described in the Supplemental Methods, were stained with MGG, TB (0.05%; 5-15 minutes), or the indicated Abs (Supplemental Table 6 ) and counterstained with hematoxylin, Hoechst 33258 (Sigma-Aldrich; dilution 1:5000), Envision (Dako), and/or avidin (Vector Laboratories). MCs were counted as a percentage of 10,000 cells on cytology or of all cells on histology. Microscopy was done on an AxioObserver D1 (Zeiss) or an SP5 (Leica Microsystems) microscopes.
Flow cytometry. After NH 4 Cl red blood cell lysis, cells were suspended in PBS 2% FBS, stained with the indicated Abs (Supplemental Table 6 ) for 20 minutes, fixed in 1 % paraformaldehyde (10 minutes), and analyzed on a FACSCalibur (BD Biosciences). Data were examined using FlowJo. electroblotted to PVDF membranes (Millipore). Membranes were probed with specific Ab (Supplemental Table 6 ), and were visualized by enhanced chemiluminescence. Cellular assays. Tumor cell proliferation in response to IL-1β or BMMC-CM was determined using MTT reduction (Promega). MC migration was studied in Boyden chambers with 8.0 μm pores (36): cancer cells were cultured in the lower and bioluminescent BMMCs in the upper chambers. After 48 hours, the upper chambers were removed and the bioluminescent signal of transmigrated BMMCs was measured by imaging. MC histamine was measured by the o-phthalaldehyde method (58) . All cellular experiments were done at least 3 times, while 1 representative experiment is shown.
Statistics. Sample size was calculated using G*power (http:// www.gpower.hhu.de/; ref. 59) assuming α = 0.05, β = 0.8, and ρ = 0.3. No data were excluded. Animals were allocated to treatments by alternation, and transgenic animals were enrolled case-controlwise. Data acquisition was blinded on samples previously coded by a nonblinded investigator. All data were examined for normality by Kolmogorov-Smirnof test. Values are given as mean ± SD and median ± interquartile range, as indicated. Sample size (n) refers to biological replicates. Differences in means were examined by Bioluminescence imaging. Cells and mice were imaged after the addition of 300 μg/ml D-luciferin to culture media or i.v. delivery of 1 mg D-luciferin on a Xenogen Lumina II. Data were analyzed on Living Image v.4.2 (PerkinElmer) (47, 48) .
Vascular permeability assays. Mice with MPEs received 0.8 mg Evans' blue i.v. and were killed after 1 hour for determination of MPE levels of the albumin tracer (48) . Intradermal injections of test molecules (1.5 ng/50 μl PBS), cell-free MPEs (50 μl), or cancer cellconditioned media (50 μl) were followed by Evans' blue injection as above, and euthanasia, skin inversion and imaging after 1 hour (25) . Dye leak was determined using Fiji (http://fiji.sc/Fiji).
qPCR and microarray. RNA was isolated using Trizol (Invitrogen) followed by RNAeasy (QIAGEN), RNA was reverse transcribed using Superscript III (Invitrogen), and reverse transcriptase or qPCR was performed using specific primers (Supplemental Table 7 ). For microarray, 5 μg RNA pooled from triplicate samples was tested for quality, labeled, and hybridized to GeneChip Mouse Gene 1.0 or 2.0 ST arrays (Affymetrix). Data (http://www.ncbi.nlm.nih.gov/geo/; Accession ID: GSE58190) were analyzed as detailed in the Supplemental Methods.
Immunoblotting. Nuclear and cytoplasmic extracts were prepared using NE-PER (Thermo), separated by 10% SDS-PAGE, and 2-tailed Student's t test, or 1-way or 2-way ANOVA with Bonferroni post-tests, as appropriate, and in medians by Mann-Whitney U test or Kruskal-Wallis test with Dunn's post hoc tests. Correlations were done using Pearson's r or Spearman's ρ. P values are 2-tailed, and P < 0.05 was considered significant. Analyses and plots were done on Prism v5.0 (GraphPad Software). Figure 1A . (E) Graphical summary of present work: pleural adenocarcinomas secrete CCL2 and SPP1, which facilitate, respectively, pleural MC accumulation and activation. Upon tumor cell encounter, MCs release TPSAB1 and IL-1β, which increase vascular leakage and tumor NF-κB activation, respectively. Data presented as data points and median ± interquartile range (D) or mean ± SD (all other graphs). Cytokine measurements in (B) were repeated 3 times; shown are data from 1 experiment. Numbers in boxes indicate sample size. NS, P > 0.05; *P < 0.05; **P < 0.01; and ***P < 0.001, by Student's t test (A-C) or Kruskal-Wallis ANOVA with Dunn's post hoc tests (D).
